<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="{font-family : courier ; font-style : italic;} Infect Dis RepIDRInfectious" exact="Disease" post="Reports2036-74302036-7449PAGEPress Publications, Pavia, Italy pmcid: 7097833 pmid: 32218915 doi:"/>
 <result pre="32218915 doi: 10.4081/idr.2020.8543 : Expert Opinion National Institute for the" exact="Infectious" post="Diseases &quot;L. Spallanzani&quot;, IRCCS. Recommendations for COVID-19 clinical management"/>
 <result pre="doi: 10.4081/idr.2020.8543 : Expert Opinion National Institute for the Infectious" exact="Diseases" post="&quot;L. Spallanzani&quot;, IRCCS. Recommendations for COVID-19 clinical management NicastriEmanuelePetrosilloNicolaAscoli"/>
 <result pre="BartoliTommasoLeporeLucianaMondiAnnalisaPalmieriFabrizioD’OffiziGianpieroMarchioniLuisaMurachelliSilviaIppolitoGiuseppeAntinoriAndreafor the INMI COVID-19 Treatment Group (ICOTREG)*[], National Institute for" exact="Infectious" post="Diseases &quot;L. Spallanzani&quot;IRCCS, Rome, Italy National Institute for Infectious"/>
 <result pre="the INMI COVID-19 Treatment Group (ICOTREG)*[], National Institute for Infectious" exact="Diseases" post="&quot;L. Spallanzani&quot;IRCCS, Rome, Italy National Institute for Infectious Diseases"/>
 <result pre="for Infectious Diseases &quot;L. Spallanzani&quot;IRCCS, Rome, Italy National Institute for" exact="Infectious" post="Diseases &quot;L. Spallanzani&quot;, IRCCS, Via Portuense 292, 00149 Rome,"/>
 <result pre="Infectious Diseases &quot;L. Spallanzani&quot;IRCCS, Rome, Italy National Institute for Infectious" exact="Diseases" post="&quot;L. Spallanzani&quot;, IRCCS, Via Portuense 292, 00149 Rome, Italy."/>
 <result pre="a novel coronavirus, further classified as SARS-CoV-2 responsible of a" exact="disease" post="(COVID-19) ranging from asymptomatic cases to severe respiratory involvement."/>
 <result pre="of a disease (COVID-19) ranging from asymptomatic cases to severe" exact="respiratory" post="involvement. On March 9 2020, WHO declared COVID-19 a"/>
 <result pre="pandemic. Italy is the second most affected country by COVID-19" exact="infection" post="after China. The &quot;L. Spallanzani&quot; National Institute for the"/>
 <result pre="infection after China. The &quot;L. Spallanzani&quot; National Institute for the" exact="Infectious" post="Diseases, IRCCS, Rome, Italy, has been the first Italian"/>
 <result pre="recommendations for the management of COVID-19 patients, based on very" exact="limited" post="clinical evidences; they should be considered as expert opinions,"/>
 <result pre="December 2019, led to a sharply spreading outbreak of human" exact="respiratory" post="disease (COVID-2019), both within People’s Republic of China and"/>
 <result pre="2019, led to a sharply spreading outbreak of human respiratory" exact="disease" post="(COVID-2019), both within People’s Republic of China and in"/>
 <result pre="Currently, Italy is the second most affected country by COVID-19" exact="infection" post="after China. The first autochthonous infection case was confirmed"/>
 <result pre="affected country by COVID-19 infection after China. The first autochthonous" exact="infection" post="case was confirmed in Italy on February 21 2020"/>
 <result pre="the next days. The &quot;L. Spallanzani&quot; National Institute for the" exact="Infectious" post="Diseases, IRCCS has been the first Italian hospital to"/>
 <result pre="in order to support other facilities that may have a" exact="limited" post="experience in treating COVID-19 patients. Procedures described in the"/>
 <result pre="are applied in agreement with the &quot;Regional Network for the" exact="Infectious" post="Diseases&quot;, the &quot;Regional Hospital and Medical Specialties Network&quot; and"/>
 <result pre="network. Recommendations described within this document are based on very" exact="limited" post="clinical evidences. Consequently, they should be considered as expert"/>
 <result pre="COVID-19 case definition Suspected case a. A person with an" exact="acute" post="respiratory infection (defined as acute onset of at least"/>
 <result pre="case definition Suspected case a. A person with an acute" exact="respiratory" post="infection (defined as acute onset of at least one"/>
 <result pre="definition Suspected case a. A person with an acute respiratory" exact="infection" post="(defined as acute onset of at least one of"/>
 <result pre="a. A person with an acute respiratory infection (defined as" exact="acute" post="onset of at least one of the following sign/symptoms:"/>
 <result pre="of at least one of the following sign/symptoms: fever, cough," exact="respiratory" post="difficulty breathing) and without another etiology which completely explains"/>
 <result pre="days preceding symptoms onset OR b. A person with an" exact="acute" post="respiratory infection and history of close contact with a"/>
 <result pre="preceding symptoms onset OR b. A person with an acute" exact="respiratory" post="infection and history of close contact with a probable"/>
 <result pre="symptoms onset OR b. A person with an acute respiratory" exact="infection" post="and history of close contact with a probable or"/>
 <result pre="preceding symptoms onset OR c. A person with a severe" exact="respiratory" post="infection (fever and at least one sign/symptom of respiratory"/>
 <result pre="symptoms onset OR c. A person with a severe respiratory" exact="infection" post="(fever and at least one sign/symptom of respiratory disease"/>
 <result pre="severe respiratory infection (fever and at least one sign/symptom of" exact="respiratory" post="disease e.g. cough or difficulty breathing) and who require"/>
 <result pre="respiratory infection (fever and at least one sign/symptom of respiratory" exact="disease" post="e.g. cough or difficulty breathing) and who require hospital"/>
 <result pre="which completely explains the clinical presentation In the setting of" exact="primary" post="care/AE department in countries/areas where autochthonous transmission has been"/>
 <result pre="autochthonous transmission has been observed, all patients with sings/symptoms of" exact="acute" post="respiratory infection should be considered as suspected cases. *According"/>
 <result pre="transmission has been observed, all patients with sings/symptoms of acute" exact="respiratory" post="infection should be considered as suspected cases. *According to"/>
 <result pre="has been observed, all patients with sings/symptoms of acute respiratory" exact="infection" post="should be considered as suspected cases. *According to WHO"/>
 <result pre="symptoms. Clinical management based on case severity Asymptomatic or mild" exact="infection" post="Cases not presenting any clinical feature suggesting a complicated"/>
 <result pre="goals of clinical management are: Application of strict measures of" exact="infection" post="prevention Clinical monitoring, in order to early identify possible"/>
 <result pre="signs of clinical worsening The application of strict measures of" exact="infection" post="prevention should be applied for all patients with suspected"/>
 <result pre="infection, regardless of clinical severity. Characteristics: No symptoms or mild" exact="upper" post="respiratory tract manifestations; stable clinical picture Minimal additional microbiologic"/>
 <result pre="regardless of clinical severity. Characteristics: No symptoms or mild upper" exact="respiratory" post="tract manifestations; stable clinical picture Minimal additional microbiologic diagnostics:"/>
 <result pre="severity. Characteristics: No symptoms or mild upper respiratory tract manifestations;" exact="stable" post="clinical picture Minimal additional microbiologic diagnostics: Influenza virus detection"/>
 <result pre="clinical picture Minimal additional microbiologic diagnostics: Influenza virus detection and/or" exact="respiratory" post="agents multiplex PCR on single rhinopharyngeal swab sample SARS-CoV-2"/>
 <result pre="re-evaluation (once/work shift; thrice/day) Periodic vital signs recording (blood pressure," exact="heart" post="rate, respiratory rate, SpO2, GCS, body temperature) (once/work shift,"/>
 <result pre="shift; thrice/day) Periodic vital signs recording (blood pressure, heart rate," exact="respiratory" post="rate, SpO2, GCS, body temperature) (once/work shift, thrice/day) Virologic"/>
 <result pre="of cough and/or clinical examination suggesting possible lung Involvement, perform" exact="chest" post="X-ray Antiviral therapy: none Supportive therapy: Symptoms control Stable"/>
 <result pre="perform chest X-ray Antiviral therapy: none Supportive therapy: Symptoms control" exact="Stable" post="patient presenting with respiratory and/or systemic symptoms (e.g. MEWS"/>
 <result pre="therapy: none Supportive therapy: Symptoms control Stable patient presenting with" exact="respiratory" post="and/or systemic symptoms (e.g. MEWS clinical deterioration score &amp;lt;3)"/>
 <result pre="Supportive therapy: Symptoms control Stable patient presenting with respiratory and/or" exact="systemic" post="symptoms (e.g. MEWS clinical deterioration score &amp;lt;3) Individuals presenting"/>
 <result pre="of clinical conditions and analytical data Strategy aimed at accelerating" exact="viral" post="clearance, through use of potentially efficacious experimental antiviral drugs"/>
 <result pre="involvement No clinical or laboratoristic parameters of clinical severity and/or" exact="respiratory" post="impairment Additional microbiologic diagnostics: Influenza virus detection and/or respiratory"/>
 <result pre="and/or respiratory impairment Additional microbiologic diagnostics: Influenza virus detection and/or" exact="respiratory" post="agents multiplex PCR on single rhinopharyngeal swab sample SARS-CoV-2"/>
 <result pre="antigen detection In case of availability of samples representative of" exact="lower" post="respiratory tract (e.g. sputum), perform gram stain and culture;"/>
 <result pre="detection In case of availability of samples representative of lower" exact="respiratory" post="tract (e.g. sputum), perform gram stain and culture; avoid"/>
 <result pre="avoid aerosol-generating procedures to induce sputum, because of the higher" exact="infectious" post="risk for healthcare workers In case of fever (&amp;gt;"/>
 <result pre="re-evaluation (once/work shift; thrice/day) Periodic vital signs recording (blood pressure," exact="heart" post="rate, respiratory rate, SpO2, GCS, body temperature) (once/work shift,"/>
 <result pre="shift; thrice/day) Periodic vital signs recording (blood pressure, heart rate," exact="respiratory" post="rate, SpO2, GCS, body temperature) (once/work shift, thrice/day), in"/>
 <result pre="in order to early identify a possible rapid worsening of" exact="respiratory" post="functions requiring an increase of the level of care"/>
 <result pre="q12, during 14 days. ** Before chloroquine and hydrossichloroquine administration," exact="G6PD deficiency" post="test should be performed. Supportive therapy: Symptomatic Oral rehydration"/>
 <result pre="during 14 days. ** Before chloroquine and hydrossichloroquine administration, G6PD" exact="deficiency" post="test should be performed. Supportive therapy: Symptomatic Oral rehydration"/>
 <result pre="availability of O2, in case of necessity Patient affected by" exact="respiratory" post="symptoms, clinically unstable, not in critical conditions (e.g.: MEWS"/>
 <result pre="conditions (e.g.: MEWS clinical deterioration score 3-4) Patients presenting severe" exact="respiratory" post="conditions related to SARS-CoV-2 infection and/or to its complications."/>
 <result pre="score 3-4) Patients presenting severe respiratory conditions related to SARS-CoV-2" exact="infection" post="and/or to its complications. Adjunctive goals of clinical management"/>
 <result pre="the level of care, whenever required Maintenance of an adequate" exact="peripheral" post="oxygenation, through O2 administration Use of potentially efficacious antiviral"/>
 <result pre="of potentially efficacious antiviral experimental drugs, aimed at rapidly reducing" exact="viral" post="replication Empirical or targeted treatment of possible bacterial co-infections;"/>
 <result pre="rapidly reducing viral replication Empirical or targeted treatment of possible" exact="bacterial" post="co-infections; Prompt assessment of the need of drugs aimed"/>
 <result pre="laboratoristic evidence of worsening of gas exchange (mild-tomoderate dyspnoea, high" exact="respiratory" post="rate, shortness of breath, low peripheral SpO2 or altered"/>
 <result pre="exchange (mild-tomoderate dyspnoea, high respiratory rate, shortness of breath, low" exact="peripheral" post="SpO2 or altered arterial blood gases while breathing room"/>
 <result pre="breathing room air), without any critical or warning signs (severe" exact="respiratory" post="failure, respiratory distress, consciousness disorders, hypotension, shock) Additional microbiologic"/>
 <result pre="air), without any critical or warning signs (severe respiratory failure," exact="respiratory" post="distress, consciousness disorders, hypotension, shock) Additional microbiologic diagnostics: Influenza"/>
 <result pre="disorders, hypotension, shock) Additional microbiologic diagnostics: Influenza virus detection and/or" exact="respiratory" post="agents multiplex PCR on single rhinopharyngeal swab sample SARS-CoV-2"/>
 <result pre="antigen detection In case of availability of sample representative of" exact="lower" post="respiratory tract (e.g. sputum), perform gram stain and culture;"/>
 <result pre="detection In case of availability of sample representative of lower" exact="respiratory" post="tract (e.g. sputum), perform gram stain and culture; avoid"/>
 <result pre="avoid aerosol-generating procedures to induce sputum, because of the higher" exact="infectious" post="risk for healthcare workers In case of fever (&amp;gt;38˚C),"/>
 <result pre="specific clinical picture (e.g. HIV test, P. jirovecii detection on" exact="respiratory" post="fluids, MRSA on nasal swab, etc…) Clinical monitoring: Strict"/>
 <result pre="on nasal swab, etc…) Clinical monitoring: Strict clinical re-evaluation Strict" exact="periodic" post="vital signs recording (blood pressure, heart rate, respiratory rate,"/>
 <result pre="Strict clinical re-evaluation Strict periodic vital signs recording (blood pressure," exact="heart" post="rate, respiratory rate, SpO2, GCS, body temperature), in order"/>
 <result pre="re-evaluation Strict periodic vital signs recording (blood pressure, heart rate," exact="respiratory" post="rate, SpO2, GCS, body temperature), in order to early"/>
 <result pre="in order to early identify a possible rapid worsening of" exact="respiratory" post="functions, requiring an increase of the level of care"/>
 <result pre="be performed in every patient affected by lung involvement causing" exact="respiratory" post="failure. Use of contrast only in case of specific"/>
 <result pre="of contrast only in case of specific clinical questions (e.g." exact="pulmonary" post="embolism). Chest CT report should be evaluated together with"/>
 <result pre="q12, during 14 days. ** Before chloroquine and hydroxychloroquine administration," exact="G6PD deficiency" post="test should be performed ° Do not co-administrate Remdesivir"/>
 <result pre="during 14 days. ** Before chloroquine and hydroxychloroquine administration, G6PD" exact="deficiency" post="test should be performed ° Do not co-administrate Remdesivir"/>
 <result pre="criteria: a) PaO2/Fi02 ratio &amp;lt;300 mmHg; b) rapid worsening of" exact="respiratory" post="gas exchange with or without availability of non-invasive or"/>
 <result pre="or based on microbiological results) Oral or intravenous rehydration Consider" exact="systemic" post="steroids administration in case of clinical signs suggesting an"/>
 <result pre="in case of clinical signs suggesting an incipient worsening of" exact="respiratory" post="functions (steroids are mandatory if Tocilizumab is used) (methylprednisolone"/>
 <result pre="Patient affected by a very severe illness, due to severe" exact="respiratory" post="failure or severe impairment of other vital functions. Main"/>
 <result pre="at reducing the impact of inflammatory response to ARDS Characteristics:" exact="Acute respiratory distress syndrome" post="(ARDS) Severe respiratory failure, respiratory distress Hypotension - Shock"/>
 <result pre="reducing the impact of inflammatory response to ARDS Characteristics: Acute" exact="respiratory" post="distress syndrome (ARDS) Severe respiratory failure, respiratory distress Hypotension"/>
 <result pre="impact of inflammatory response to ARDS Characteristics: Acute respiratory distress" exact="syndrome" post="(ARDS) Severe respiratory failure, respiratory distress Hypotension - Shock"/>
 <result pre="inflammatory response to ARDS Characteristics: Acute respiratory distress syndrome (ARDS)" exact="Severe" post="respiratory failure, respiratory distress Hypotension - Shock Multiorgan failure"/>
 <result pre="response to ARDS Characteristics: Acute respiratory distress syndrome (ARDS) Severe" exact="respiratory" post="failure, respiratory distress Hypotension - Shock Multiorgan failure (MOF)"/>
 <result pre="ARDS Characteristics: Acute respiratory distress syndrome (ARDS) Severe respiratory failure," exact="respiratory" post="distress Hypotension - Shock Multiorgan failure (MOF) Consciousness impairment"/>
 <result pre="Acute respiratory distress syndrome (ARDS) Severe respiratory failure, respiratory distress" exact="Hypotension" post="- Shock Multiorgan failure (MOF) Consciousness impairment Additional microbiologic"/>
 <result pre="distress syndrome (ARDS) Severe respiratory failure, respiratory distress Hypotension -" exact="Shock" post="Multiorgan failure (MOF) Consciousness impairment Additional microbiologic diagnostics: Influenza"/>
 <result pre="(MOF) Consciousness impairment Additional microbiologic diagnostics: Influenza virus detection and/or" exact="respiratory" post="agents multiplex PCR on single rhinopharyngeal swab sample SARS-CoV-2"/>
 <result pre="antigen detection In case of availability of samples representative of" exact="lower" post="respiratory tract (e.g.: sputum), perform gram stain and culture;"/>
 <result pre="detection In case of availability of samples representative of lower" exact="respiratory" post="tract (e.g.: sputum), perform gram stain and culture; avoid"/>
 <result pre="avoid aerosol-generating procedures to induce sputum, because of the higher" exact="infectious" post="risk for healthcare workers In case of fever (&amp;gt;"/>
 <result pre="specific clinical picture (e.g. HIV test, P. jirovecii detection on" exact="respiratory" post="fluids, MRSA on nasal swab, etc…) Clinical monitoring: Strict"/>
 <result pre="hours until persistently negative SARS-CoV-2 RT-PCR performed on samples representing" exact="lower" post="respiratory tract, using the same timing IL-6 plasma levels"/>
 <result pre="until persistently negative SARS-CoV-2 RT-PCR performed on samples representing lower" exact="respiratory" post="tract, using the same timing IL-6 plasma levels D-dimer,"/>
 <result pre="be performed in every patient affected by lung involvement causing" exact="respiratory" post="failure. Use of contrast only in case of specific"/>
 <result pre="of contrast only in case of specific clinical questions (e.g." exact="pulmonary" post="embolism). The exam is required by the intensive care"/>
 <result pre="q12, during 14 days. ** Before chloroquine and hydrossichloroquine administration," exact="G6PD deficiency" post="test should be performed ° Do not co-administrate Remdesivir"/>
 <result pre="during 14 days. ** Before chloroquine and hydrossichloroquine administration, G6PD" exact="deficiency" post="test should be performed ° Do not co-administrate Remdesivir"/>
 <result pre="criteria: a) PaO2/Fi02 ratio &amp;lt;300 mmHg; b) rapid worsening of" exact="respiratory" post="gas exchange with or without availability of non-invasive or"/>
 <result pre="ventilation as recommended for patients affected by ARDS sustainted by" exact="viral" post="interstitial pneumonia Antimicrobial therapy (broad spectrumempiric or based on"/>
 <result pre="recommended for patients affected by ARDS sustainted by viral interstitial" exact="pneumonia" post="Antimicrobial therapy (broad spectrumempiric or based on microbiological results)"/>
 <result pre="results) Intensive care and monitoring as indicated by hospital protocols" exact="Systemic" post="steroid therapy in case of ARDS/severe respiratory failure (steroids"/>
 <result pre="by hospital protocols Systemic steroid therapy in case of ARDS/severe" exact="respiratory" post="failure (steroids are mandatory if Tocilizumab is used) (methylprednisolone"/>
 <result pre="Kigali adaptation for low resource settings) Onset: new or worsening" exact="respiratory" post="symptoms within one week of known clinical insult Chest"/>
 <result pre="clinical insult Chest imaging (radiograph, CT scan, or lung ultrasound):" exact="bilateral" post="opacities, not fully explained by effusions, lobar or lung"/>
 <result pre="effusions, lobar or lung collapse, or nodules Origin of oedema:" exact="respiratory" post="failure not fully explained by cardiac failure or fluid"/>
 <result pre="&amp;lt; PaO2/FiO2 ≤200 mmHg with PEEP ≥5 cmH2O, or non-ventilated)" exact="Severe" post="ARDS: PaO2/FiO2 ≤ 100 mmHg with PEEP ≥5 cmH2O,"/>
 <result pre="≤ OI &amp;lt; 16 or 7.5 ≤ OSI &amp;lt; 12.3" exact="Severe" post="ARDS (invasively ventilated): OI ≥ 16 or OSI ≥"/>
 <result pre="a potential antiviral effect of this drug against SARS and" exact="avian influenza" post="H5N1. Mechanism of Action It has been postulated that"/>
 <result pre="the change of cell membrane pH which is necessary for" exact="viral" post="fusion and the interference with glycosylation of viral proteins."/>
 <result pre="necessary for viral fusion and the interference with glycosylation of" exact="viral" post="proteins. Hydroxychloroquine, an analogue of chloroquine, has been proved"/>
 <result pre="in reducing both the severity and the duration of clinical" exact="disease" post="without significant adverse events in almost one hundred patients."/>
 <result pre="for COVID-19 treatment. Dosage The recommended dosage for SARSCoV- 2" exact="infection" post="is chloroquine 500 mg bid or hydroxychloroquine 200 mg"/>
 <result pre="may include: QT prolongation &amp;amp; torsades de pointes, reduction in" exact="seizure" post="threshold, anaphylaxis or anaphylactoid reaction, neuromuscular impairment, neuropsychiatric disorders"/>
 <result pre="impairment, neuropsychiatric disorders (potential to increase delirium), pancytopenia, neutropenia, thrombocytopenia," exact="aplastic anemia," post="hepatitis. Common adverse reactions: nausea/ vomiting, diarrhea, abdominal pain,"/>
 <result pre="anemia, hepatitis. Common adverse reactions: nausea/ vomiting, diarrhea, abdominal pain," exact="visual" post="disturbance, headache, extrapyramidal symptoms It is important to check"/>
 <result pre="adverse reactions: nausea/ vomiting, diarrhea, abdominal pain, visual disturbance, headache," exact="extrapyramidal symptoms" post="It is important to check G6PDH before starting treatment"/>
 <result pre="check G6PDH before starting treatment and during treatment to monitor" exact="complete" post="blood count, QT interval. Contraindicated in: Porphyria, G6PD deficiency,"/>
 <result pre="to monitor complete blood count, QT interval. Contraindicated in: Porphyria," exact="G6PD deficiency," post="epilepsy, heart failure, recent myocardial infarction. Lopinavir/ritonavir Lopinavir/ritonavir is"/>
 <result pre="blood count, QT interval. Contraindicated in: Porphyria, G6PD deficiency, epilepsy," exact="heart" post="failure, recent myocardial infarction. Lopinavir/ritonavir Lopinavir/ritonavir is a well-known"/>
 <result pre="interval. Contraindicated in: Porphyria, G6PD deficiency, epilepsy, heart failure, recent" exact="myocardial infarction." post="Lopinavir/ritonavir Lopinavir/ritonavir is a well-known protease inhibitor which has"/>
 <result pre="been widely used for many years for the treatment of" exact="HIV infection." post="Compared to remdesivir, lopinavir/ritonavir has the advantage that it’s"/>
 <result pre="established toxicity and drug-drug interactions profile. Its antiviral action against" exact="coronavirus infections" post="has been previously demonstrated both in-vitro and in-vivo (animal"/>
 <result pre="toxicity and drug-drug interactions profile. Its antiviral action against coronavirus" exact="infections" post="has been previously demonstrated both in-vitro and in-vivo (animal"/>
 <result pre="trial (RCTs) on lopinavir/ritonavir combined with IFNb use in MERS" exact="infection" post="is currently ongoing [MIRACLE Trial]. Mechanism of Action Lopinavir"/>
 <result pre="Mechanism of Action Lopinavir act its antiviral activity by inhibiting" exact="viral" post="replication. As in HIV infection, ritonavir only acts boosting"/>
 <result pre="act its antiviral activity by inhibiting viral replication. As in" exact="HIV infection," post="ritonavir only acts boosting lopinavir plasma levels. Available data"/>
 <result pre="boosting lopinavir plasma levels. Available data on SARS-COV2 Although only" exact="limited" post="and anecdotal data are available of the clinical efficacy"/>
 <result pre="are available of the clinical efficacy of lopinavir/ritonavir in COVID-19" exact="infection" post="so far, it seems to rapidly reduce SARSCoV2 replication."/>
 <result pre="cannot be crushed). Adverse Events/Cautions Serious adverse effects may include:" exact="Hypersensitivity" post="reaction, angioedema, Stevens-Johnson syndrome and Toxic epidermal necrolysis, EKG"/>
 <result pre="Adverse Events/Cautions Serious adverse effects may include: Hypersensitivity reaction, angioedema," exact="Stevens-Johnson syndrome" post="and Toxic epidermal necrolysis, EKG alterations (QT prolongation &amp;amp;"/>
 <result pre="Events/Cautions Serious adverse effects may include: Hypersensitivity reaction, angioedema, Stevens-Johnson" exact="syndrome" post="and Toxic epidermal necrolysis, EKG alterations (QT prolongation &amp;amp;"/>
 <result pre="adverse effects may include: Hypersensitivity reaction, angioedema, Stevens-Johnson syndrome and" exact="Toxic epidermal necrolysis," post="EKG alterations (QT prolongation &amp;amp; Torsade de Pointes, AV"/>
 <result pre="epidermal necrolysis, EKG alterations (QT prolongation &amp;amp; Torsade de Pointes," exact="AV block," post="PR prolongation), pancytopenia, Pancreatitis, Hepatotoxicity Common adverse reactions: gastrointestinal"/>
 <result pre="infection. Remdesevir has shown clinical an excellent activity against other" exact="coronavirus infections" post="(SARS, MERS) both in-vitro and in animal models. Mechanism"/>
 <result pre="Remdesevir has shown clinical an excellent activity against other coronavirus" exact="infections" post="(SARS, MERS) both in-vitro and in animal models. Mechanism"/>
 <result pre="in animal models. Mechanism of Action It acts by inhibiting" exact="viral" post="polymerase Available data on SARS-COV2 A recent study exploring"/>
 <result pre="sIL- 6R and mIL-6R. The main approved indication is for" exact="rheumatoid arthritis," post="in association or not with methotrexate. In 2017, the"/>
 <result pre="Drug Administration approved TCZ for the treatment of cytokine release" exact="syndrome" post="(CRS) consisting in a systemic inflammatory response caused by"/>
 <result pre="the treatment of cytokine release syndrome (CRS) consisting in a" exact="systemic" post="inflammatory response caused by the massive release of pro-inflammatory"/>
 <result pre="pro-inflammatory cytokines in response to iatrogenic (e.g. CAR-t therapies) or" exact="infective" post="stimuli. Available data on SARS-COV2 Although the lack of"/>
 <result pre="in IL-6 plasmatic levels were observed at different stage of" exact="disease" post="with a higher expression in severe cases than mild"/>
 <result pre="autopsy from a severe COVID- 19 patient, histological examination showed" exact="diffuse" post="alveolar damage with cellular fibromyxoid exudates and interstitial mononuclear"/>
 <result pre="TCZ was recently approved for patients affected by severe SARS-CoV-2" exact="pulmonary" post="complications by the National Health Commission of the People’s"/>
 <result pre="patients who could benefit from TCZ therapy are: Patients with" exact="respiratory" post="symptoms, unstable and severe but not in critical conditions"/>
 <result pre="93% in ambient air, PaO2/FiO2 ≤ 300 mmHg) in the" exact="absence of" post="critical manifestations or signs of alarm (severe respiratory failure,"/>
 <result pre="the absence of critical manifestations or signs of alarm (severe" exact="respiratory" post="failure, respiratory distress, altered state of consciousness, hypotension, cardiovascular"/>
 <result pre="of critical manifestations or signs of alarm (severe respiratory failure," exact="respiratory" post="distress, altered state of consciousness, hypotension, cardiovascular shock); Patient"/>
 <result pre="(severe respiratory failure, respiratory distress, altered state of consciousness, hypotension," exact="cardiovascular" post="shock); Patient with respiratory symptoms in critical conditions (e.g."/>
 <result pre="distress, altered state of consciousness, hypotension, cardiovascular shock); Patient with" exact="respiratory" post="symptoms in critical conditions (e.g. clinical instability score of"/>
 <result pre="in case of: Absence/poor clinical improvement or clinical worsening and/or" exact="Failure" post="in reduction of 50% baseline Creactive protein (a reliable"/>
 <result pre="reliable surrogate marker of IL-6) or failure in normalization and/or" exact="Failure" post="in reduction in D-dimer, fibrinogen or ferritin levels. Dosage"/>
 <result pre="levels. Dosage adjustment is required in relation to blood parameters" exact="of liver" post="function and blood count according to the indications specified"/>
 <result pre="24h after 2nd infusion, 36h after 2nd infusion. Adverse events/cautions" exact="Severe" post="life-threatening infections and alterations in blood parameters as ALT"/>
 <result pre="2nd infusion, 36h after 2nd infusion. Adverse events/cautions Severe life-threatening" exact="infections" post="and alterations in blood parameters as ALT / AST"/>
 <result pre="treatment. Caution is required in special categories: pregnancy/breastfeeding, active /latent" exact="pulmonary tuberculosis," post="bacterial/fungal infections, immune-related rheumatic disease or concomitant therapy with"/>
 <result pre="special categories: pregnancy/breastfeeding, active /latent pulmonary tuberculosis, bacterial/fungal infections, immune-related" exact="rheumatic" post="disease or concomitant therapy with anti-rejection drugs or immunomodulating"/>
 <result pre="categories: pregnancy/breastfeeding, active /latent pulmonary tuberculosis, bacterial/fungal infections, immune-related rheumatic" exact="disease" post="or concomitant therapy with anti-rejection drugs or immunomodulating therapies,"/>
 <result pre="concomitant therapy with anti-rejection drugs or immunomodulating therapies, hepatopaties (including" exact="viral" post="hepatitis). The safety profile of TCZ is well known."/>
 <result pre="in neutrophil counts increased with the higher dose of TCZ." exact="Thrombocytopenia" post="and increase of liver function tests have also been"/>
 <result pre="increased with the higher dose of TCZ. Thrombocytopenia and increase" exact="of liver" post="function tests have also been described. For more detailed"/>
 <result pre="Zaccarelli M, Zaccaro G. References References collab: European Centre for" exact="Disease" post="Prevention and Control. Rapid Risk Assessment: Novel coronavirus disease"/>
 <result pre="Centre for Disease Prevention and Control. Rapid Risk Assessment: Novel" exact="coronavirus disease" post="2019 (COVID-2019) pandemic: increased transmission in the EU/EEA –"/>
 <result pre="for Disease Prevention and Control. Rapid Risk Assessment: Novel coronavirus" exact="disease" post="2019 (COVID-2019) pandemic: increased transmission in the EU/EEA –"/>
 <result pre="on March 13 2020. collab: WHO. Global Surveillance for human" exact="infection" post="with coronavirus disease (COVID-2019). Revised guidance, 27 February2020 Available"/>
 <result pre="13 2020. collab: WHO. Global Surveillance for human infection with" exact="coronavirus disease" post="(COVID-2019). Revised guidance, 27 February2020 Available at https://www.who.int/publications-detail/global-surveillance-for-human-infectionwith-novel-coronavirus-(2019-ncov), visited"/>
 <result pre="2020. collab: WHO. Global Surveillance for human infection with coronavirus" exact="disease" post="(COVID-2019). Revised guidance, 27 February2020 Available at https://www.who.int/publications-detail/global-surveillance-for-human-infectionwith-novel-coronavirus-(2019-ncov), visited"/>
 <result pre="https://www.who.int/publications-detail/global-surveillance-for-human-infectionwith-novel-coronavirus-(2019-ncov), visited on 28 February 2020. collab: European Centre for" exact="Disease" post="Prevention and Control. An agency of the European Union."/>
 <result pre="at https://www.ecdc.europa.eu/en/case-definition-and-european-surveillance-human-infectionnovel-coronavirus-2019-ncov, visited on 28 February 2020. collab: Centers for" exact="Disease" post="Control and Prevention (CDC). Interim Infection Prevention and Control"/>
 <result pre="2020. collab: Centers for Disease Control and Prevention (CDC). Interim" exact="Infection" post="Prevention and Control Recommendations for Patients with Confirmed Coronavirus"/>
 <result pre="Infection Prevention and Control Recommendations for Patients with Confirmed Coronavirus" exact="Disease" post="2019 (COVID-19) or Persons Under Investigation for COVID-19 in"/>
 <result pre="characteristics and therapeutic procedure for four cases with 2019 novel" exact="coronavirus pneumonia" post="receiving combined Chinese and Western medicine treatment. Biosci Trends"/>
 <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatment. Biosci Trends"/>
 <result pre="and clinical findings. Thorax2004;59:252-6.14985565 MomattinHMohammedKZumlaAet al.Therapeutic options for Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV)—possible lessons from a systematic review of"/>
 <result pre="clinical findings. Thorax2004;59:252-6.14985565 MomattinHMohammedKZumlaAet al.Therapeutic options for Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV)—possible lessons from a systematic review of SARS-CoV"/>
 <result pre="of therapeutic agents for the treatment of the Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV). Travel Med Infect Dis2019;30:9-18..31252170 WangMCaoRZhangLet al.Remdesivir"/>
 <result pre="therapeutic agents for the treatment of the Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV). Travel Med Infect Dis2019;30:9-18..31252170 WangMCaoRZhangLet al.Remdesivir and"/>
 <result pre="and interferon beta against MERS-CoV. Nat Commun2020;11: 222.31924756 LaiCCShihTPKoWCet al.Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease- 2019"/>
 <result pre="interferon beta against MERS-CoV. Nat Commun2020;11: 222.31924756 LaiCCShihTPKoWCet al.Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease- 2019 (COVID-19):"/>
 <result pre="beta against MERS-CoV. Nat Commun2020;11: 222.31924756 LaiCCShihTPKoWCet al.Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease- 2019 (COVID-19): The"/>
 <result pre="Hu Xi Za Zhi. 2020;43:E007.32034899 collab: ARDS Definition Task Force." exact="Acute" post="respiratory distress syndrome: the Berlin Definition. JAMA2012;307:2526-33.22797452 RivielloEDKiviriWTwagirumugabeTet al.Hospital"/>
 <result pre="Xi Za Zhi. 2020;43:E007.32034899 collab: ARDS Definition Task Force. Acute" exact="respiratory" post="distress syndrome: the Berlin Definition. JAMA2012;307:2526-33.22797452 RivielloEDKiviriWTwagirumugabeTet al.Hospital Incidence"/>
 <result pre="Berlin Definition. JAMA2012;307:2526-33.22797452 RivielloEDKiviriWTwagirumugabeTet al.Hospital Incidence and Outcomes of the" exact="Acute" post="Respiratory Distress Syndrome Using the Kigali Modification of the"/>
 <result pre="Definition. JAMA2012;307:2526-33.22797452 RivielloEDKiviriWTwagirumugabeTet al.Hospital Incidence and Outcomes of the Acute" exact="Respiratory" post="Distress Syndrome Using the Kigali Modification of the Berlin"/>
 <result pre="RivielloEDKiviriWTwagirumugabeTet al.Hospital Incidence and Outcomes of the Acute Respiratory Distress" exact="Syndrome" post="Using the Kigali Modification of the Berlin Definition. Am"/>
 <result pre="Definition. Am J Respir Crit Care Med2016;193: 52-9.26352116 KhemaniRGSmithLSZimmermanJJet al.Pediatric" exact="acute" post="respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from"/>
 <result pre="Am J Respir Crit Care Med2016;193: 52-9.26352116 KhemaniRGSmithLSZimmermanJJet al.Pediatric acute" exact="respiratory" post="distress syndrome: definition, incidence, and epidemiology: proceedings from the"/>
 <result pre="respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the" exact="Pediatric" post="Acute Lung Injury Consensus Conference. Pediatr Crit Care Med2015;16:S23-40.26035358"/>
 <result pre="distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric" exact="Acute" post="Lung Injury Consensus Conference. Pediatr Crit Care Med2015;16:S23-40.26035358 VincentMJBergeronEBenjannetSet"/>
 <result pre="Care Med2015;16:S23-40.26035358 VincentMJBergeronEBenjannetSet al.Chloroquine is a potent inhibitor of SARS" exact="coronavirus infection" post="and spread. J Virol2005;2:69. YanYZouZSunYet al.Anti-malaria drug chloroquine is"/>
 <result pre="Med2015;16:S23-40.26035358 VincentMJBergeronEBenjannetSet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. J Virol2005;2:69. YanYZouZSunYet al.Anti-malaria drug chloroquine is"/>
 <result pre="Virol2005;2:69. YanYZouZSunYet al.Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal model. Cell"/>
 <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal model. Cell Res2013;23:300-2.23208422 WangMCaoRZhangLet al.Remdesivir and"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal model. Cell Res2013;23:300-2.23208422 WangMCaoRZhangLet al.Remdesivir and"/>
 <result pre="of Optimized Dosing Design of Hydroxychloroquine for the Treatment of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis2020"/>
 <result pre="Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis2020 Mar"/>
 <result pre="Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis2020 Mar 9."/>
 <result pre="Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2). Clin Infect Dis2020 Mar 9. GaoJTianZYangX.Breakthrough:"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies. Biosci Trends2020 Feb 19. doi: 0.5582/bst.2020.01047."/>
 <result pre="of Guangdong Province for chloroquine in the treatment of novel" exact="coronavirus pneumonia." post="[Expert consensus on chloroquine phosphate for the treatment of"/>
 <result pre="initial virological and clinical findings. Thorax2004;59:252-6.14985565 ChanKSLaiSTChuCMet al.Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
 <result pre="virological and clinical findings. Thorax2004;59:252-6.14985565 ChanKSLaiSTChuCMet al.Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study."/>
 <result pre="and clinical findings. Thorax2004;59:252-6.14985565 ChanKSLaiSTChuCMet al.Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong"/>
 <result pre="al.Treatment With Lopinavir/Ritonavir or Interferon- β1b Improves Outcome of MERS-CoV" exact="Infection" post="in a Nonhuman Primate Model of Common Marmoset. J"/>
 <result pre="of clinical diagnosis and treatment of a case infected with" exact="coronavirus disease" post="2019. J Med Virol2020 Feb 19. LimJJeonSShinHYet al.Case of"/>
 <result pre="clinical diagnosis and treatment of a case infected with coronavirus" exact="disease" post="2019. J Med Virol2020 Feb 19. LimJJeonSShinHYet al.Case of"/>
 <result pre="of the Index Patient Who Caused Tertiary Transmission of COVID-19" exact="Infection" post="in Korea: the Application of Lopinavir/Ritonavir for the treatment"/>
 <result pre="the Application of Lopinavir/Ritonavir for the treatment of COVID-19 Infected" exact="Pneumonia" post="Monitored by Quantitative RT-PCR. J Korean Med Sci2020;35:e7932056407 SheahanTPSimsACLeistSRet"/>
 <result pre="infection. Proc Natl Acad Sci USA2020 Feb 13.pii:201922083 AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXSmithECet al.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
 <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonuclease. mBio2018;9:e00221-18.29511076 HolshueMLDeBoltCLindquistSet al.First Case"/>
 <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected" exact="pneumonia" post="in Wuhan, China. JAMA2020 Feb 7. XuZShiLWangYet al.Pathological findings"/>
 <result pre="JAMA2020 Feb 7. XuZShiLWangYet al.Pathological findings of COVID-19 associated with" exact="acute respiratory distress syndrome." post="Lancet Resp Med2020. doi.org/10.1016/S2213-2600(20)30076-X XiaolingXMingfengHTiantianLet al.Effective Treatment of Severe"/>
 <result pre="Feb 7. XuZShiLWangYet al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome. Lancet Resp Med2020. doi.org/10.1016/S2213-2600(20)30076-X XiaolingXMingfengHTiantianLet al.Effective Treatment"/>
 <result pre="distress syndrome. Lancet Resp Med2020. doi.org/10.1016/S2213-2600(20)30076-X XiaolingXMingfengHTiantianLet al.Effective Treatment of" exact="Severe" post="COVID-19 Patients with Tocilizumab. 2020. chinaXiv:202003.00026v1 RieglerLLJonesGPLeeDWCurrent approaches in"/>
 <result pre="RieglerLLJonesGPLeeDWCurrent approaches in the grading and management of cytokine release" exact="syndrome" post="after chimeric antigen receptor T-cell therapy. Therapeut Clin Risk"/>
</results>
